Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Go back to Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)| Merck & Co. (NYSE: MRK) | Delayed: 126.78 -2.78 (2.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $129.56 | 52 Week High | $65.46 | |||
| Open | $129.31 | 52 Week Low | $47.97 | |||
| Day High | $130.00 | P/E | 86.24 | |||
| Day Low | $125.62 | EPS | $1.47 | |||
| Volume | 9,498,891 | |||||
